Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Next Previous
X
Search
Trial Profile

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion/dextromethorphan (Primary)
  • Indications Agitation; Alzheimer's disease; Dementia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACCORD-2
  • Sponsors Axsome Therapeutics

    • Most Recent Events

    • 12 Nov 2024 According to an Axsome Therapeutics media release, topline results expected in 4Q 2024.
    • 05 Aug 2024 According to an Axsome Therapeutics media release, topline results of ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimer's disease agitation anticipated 2H 2024 and target enrollment reached.
    • 06 May 2024 According to an Axsome Therapeutics media release, this ACCORD-2 Phase 3 randomized withdrawal trial of AXS-05 in Alzheimers disease agitation is initiated and the enrollment completion anticipated mid-year 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top